Dossier assessment

Pralsetinib (RET fusion-positive NSCLC) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-168
Last updated

Report documents

  1. Extract of dossier assessment

    Pralsetinib (RET fusion-positive NSCLC) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 412 kB, EN, not accessible
  2. Dossier assessment

    Pralsetinib (RET fusion-positive NSCLC) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 878 kB, DE, not accessible

Dossier assessment

Indication:

Patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who have previously not been treated with a RET inhibitor

Result of dossier assessment:
  • Adults with advanced RET fusion-positive NSCLC whose tumours have PD-L1 expression ≥ 50% of the tumour cells; first-line therapy: added benefit not proven
  • Adults with advanced RET fusion-positive NSCLC whose tumours have PD-L1 expression < 50% of the tumour cells; first-line therapy: added benefit not proven
  • Adults with advanced RET fusion-positive NSCLC after first-line therapy with a PD-1/PD-L1 antibody as monotherapy: added benefit not proven
  • Adults with advanced RET fusion-positive NSCLC after first-line therapy with cytotoxic chemotherapy: added benefit not proven
  • Adults with advanced RET fusion-positive NSCLC after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and a platinum-containing chemotherapy: added benefit not proven.

Project details

Project no.
A21-168
Commission
Commission awarded on 14.12.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form